A detailed history of Regents Of The University Of California transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Regents Of The University Of California holds 117,315 shares of NTLA stock, worth $1.81 Million. This represents 1.47% of its overall portfolio holdings.

Number of Shares
117,315
Previous 117,315 -0.0%
Holding current value
$1.81 Million
Previous $3.23 Million 18.66%
% of portfolio
1.47%
Previous 1.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 25, 2024

BUY
$23.16 - $32.34 $136,065 - $189,997
5,875 Added 5.27%
117,315 $3.58 Million
Q2 2019

Aug 14, 2019

SELL
$13.88 - $18.41 $5.73 Million - $7.6 Million
-412,983 Reduced 78.75%
111,440 $1.82 Million
Q4 2017

Feb 13, 2018

BUY
$17.39 - $31.12 $9.12 Million - $16.3 Million
524,423
524,423 $10.1 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.17B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Regents Of The University Of California Portfolio

Follow Regents Of The University Of California and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

News

Stay updated on Regents Of The University Of California with notifications on news.